SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 13.98 |
| Enterprise Value ($M) | 13.97 |
| Book Value ($M) | 0.01 |
| Book Value / Share | 0.00 |
| Price / Book | 1,769.80 |
| NCAV ($M) | 0.01 |
| NCAV / Share | 0.00 |
| Price / NCAV | 1,820.75 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -3,102.09 |
| Return on Assets (ROA) | -7.30 |
| Return on Equity (ROE) | -451.41 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.00 |
| Current Ratio | 0.00 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 0.01 |
| Assets | 0.01 |
| Liabilities | 0.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 3.95 |
| Operating Income | -25.14 |
| Net Income | -24.99 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -24.68 |
| Cash from Investing | -0.02 |
| Cash from Financing | 23.75 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Armistice Capital, Llc | 4.99 | -47.62 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 49,907 | 274,910 | 18.15 | |
| 53,577 | 212,241 | 25.24 | |
| 111,762 | 270,790 | 41.27 | |
| 184,641 | 511,432 | 36.10 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| GLYC – GlycoMimetics, Inc. | GNLX – Genelux Corporation |
| GNPX – Genprex, Inc. | GRCE – Grace Therapeutics, Inc. |
| GTBP – GT Biopharma, Inc. |
Financial data and stock pages provided by
Fintel.io